In its largest deal of 2019 so far, Gilead Sciences has signed a 10-year collaboration with Galapagos to gain the license and option rights to all current and future Galapagos programmes in all countries outside Europe for a total deal value of up to US$9.975 B. The deal builds on the success of a 2015 partnership between the two companies to develop and commercialise filgotinib, for which US and EU regulatory submissions are expected by year-end.